Enteropathy-Associated T-Cell Lymphoma Type I, But Not Refractory Celiac Disease, Strongly Expresses CD30 and Might Benefit From Brentuximab Vedotin
David Sibon(Hôpital Necker-Enfants Malades), Olivier Hermine(Centre National de la Recherche Scientifique), Nadine Cerf–Bensussan(Université Paris Cité), Nicole Brousse(Hôpital Necker-Enfants Malades), Isabelle Radford, Virginie Verkarre(Université Paris Cité), Coralie Derrieux(Délégation Paris 5), Elizabeth Macintyre(Inserm), Georgia Malamut(Délégation Paris 5), Christophe Cellier(Assistance Publique – Hôpitaux de Paris), Bertrand Meresse(Centre Hospitalier Universitaire de Lille)
Cited by 5
Related Papers
<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
|Science|2003|3.5k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency
|New England Journal of Medicine|2003|1.8k
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
|Journal of Clinical Investigation|2008|1.8k